Log in

Relevant bibliographies by topics / Breast cancer; Novel anticancer agents

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Breast cancer; Novel anticancer agents'

Author: Grafiati

Published: 4 June 2021

Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Breast cancer; Novel anticancer agents.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Breast cancer; Novel anticancer agents"

1

Almajali, Belal, Hamid Ali Nagi Al-Jamal, Wan Rohani Wan Taib, et al. "Thymoquinone, as a Novel Therapeutic Candidate of Cancers." Pharmaceuticals 14, no. 4 (2021): 369. http://dx.doi.org/10.3390/ph14040369.

Full text

Abstract:

To date, natural products are widely used as pharmaceutical agents for many human diseases and cancers. One of the most popular natural products that have been studied for anticancer properties is thymoquinone (TQ). As a bioactive compound of Nigella sativa, TQ has shown anticancer activities through the inhibition of cell proliferation, migration, and invasion. The anticancer efficacy of TQ is being investigated in several human cancers such as pancreatic cancer, breast cancer, colon cancer, hepatic cancer, cervical cancer, and leukemia. Even though TQ induces apoptosis by regulating the expression of pro- apoptotic and anti-apoptotic genes in many cancers, the TQ effect mechanism on such cancers is not yet fully understood. Therefore, the present review has highlighted the TQ effect mechanisms on several signaling pathways and expression of tumor suppressor genes (TSG). Data from relevant published experimental articles on TQ from 2015 to June 2020 were selected by using Google Scholar and PubMed search engines. The present study investigated the effectiveness of TQ alone or in combination with other anticancer therapeutic agents, such as tyrosine kinase inhibitors on cancers, as a future anticancer therapy nominee by using nanotechnology.

APA, Harvard, Vancouver, ISO, and other styles

2

Blacquiere, Johanna M., Oana Sicora, Christopher M. Vogels, et al. "Dihydropyrimidinones containing boronic acids." Canadian Journal of Chemistry 83, no. 12 (2005): 2052–59. http://dx.doi.org/10.1139/v05-211.

Full text

Abstract:

The addition of formylphenylboronic acid derivatives to urea and ethyl acetoacetate proceeds in the absence of an additional Lewis acid catalyst to give the corresponding dihydropyrimidinones (Biginelli products) in good yields. Novel boron-containing dihydropyrimidinones have been investigated for their ability to act as anticancer agents against the breast cancer cell line MCF7.Key words: anticancer, Biginelli compounds, boronic acids, breast cancer, dihydropyrimidinones.

APA, Harvard, Vancouver, ISO, and other styles

3

Ghanta, Venkata Rao, Nagaraju Madala, Aparna Pasula, et al. "Novel dermacozine-1-carboxamides as promising anticancer agents with tubulin polymerization inhibitory activity." RSC Advances 9, no. 32 (2019): 18670–77. http://dx.doi.org/10.1039/c9ra02416f.

Full text

Abstract:

In the present study, novel dermacozine-1-carboxamides (8a–8n) were synthesized and screened for their in vitro cytotoxic activity against three different cancer cell lines: MCF-7 (breast cancer), A-549 (lung cancer) and DU145 (prostate cancer).

APA, Harvard, Vancouver, ISO, and other styles

4

Zhang, Ya-Zhou, Hai-Lin Liu, Qian-Song He, and Zhi Xu. "The In Vitro Anticancer Activity and Potential Mechanism of Action of 1-[(1R,2S)-2-fluorocyclopropyl]Ciprofloxacin-(4-methyl/phenyl/benzyl-3- aryl)-1,2,4-triazole-5(4H)-thione Hybrids." Current Topics in Medicinal Chemistry 20, no. 16 (2020): 1493–98. http://dx.doi.org/10.2174/1568026620666200310123723.

Full text

Abstract:

Aims: Development of 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)- thione hybrids as potential dual-acting mechanism anticancer agent to overcome the drug resistance. Background: Chemotherapy is an essential tool for the treatment of lung and female breast cancers, and numerous anticancer agents have been launched for this purpose. However, the clinical outcomes of chemotherapy are usually far from satisfactory due to the side effects and resistance to chemotherapeutic drugs. Thus, it is urgent to develop novel anti-lung and anti-breast cancer agents. Background: Chemotherapy is an essential tool for the treatment of lung and female breast cancers, and numerous anticancer agents have been launched for this purpose. However, the clinical outcomes of chemotherapy are usually far from satisfactory due to the side effects and resistance to chemotherapeutic drugs. Thus, it is urgent to develop novel anti-lung and anti-breast cancer agents. Objective: The primary objective of this study was to evaluate the potential of bis-isatin scaffolds with alkyl/ether linkers between the two isatin moieties against different human breast cancer cell lines including A549, MCF-7 and their drug-resistant counterparts A549/CDDP, MCF-7/ADM cells. Methods: The 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-(4-methyl/phenyl/benzyl-3-aryl)-1,2,4- triazole-5(4H)-thione hybrids were screened for their in vitro activity against drug-sensitive lung (A549), breast (MCF-7) and their drug-resistant counterparts A549/CDDP (cisplatin-resistant), MCF- 7/ADM (doxorubicin-resistant) cancer cell lines by MTT assay. The inhibitory activity of these hybrids against topoisomerase II and EGFR was also evaluated to investigate the potential mechanism of action of these hybrids. Result: The most prominent hybrid 7k (IC50: 37.28-49.05 µM) was comparable to Vorinostat against A549 and A549/CDDP lung cancer cells, and was 2.79-2.94 times more active than Vorinostat against MCF-7 and MCF-7/ADM breast cancer cell lines. Moreover, hybrid 7k (IC50: 8.6 and 16.4 µM) also demonstrated dual inhibition against topoisomerase II and EGFR. Conclusion: The 1-[(1R, 2S)-2-fluorocyclopropyl]ciprofloxacin-1,2,4-triazole-5(4H)-thione hybrids possess equally activity against both drug-sensitive cancer cells and their drug-resistant counterparts, and the majority of them were no inferior to the reference Vorinostat. The mechanistic study revealed that these hybrids could inhibit both topoisomerase II and EGFR, so these hybrids can be developed as dual-acting mechanism anticancer agents.

APA, Harvard, Vancouver, ISO, and other styles

5

Shaik, Afzal B., Yejella R. Prasad, Srinath Nissankararao, and Shaik Shahanaaz. "Synthesis, Biological and Computational Evaluation of Novel 2,3-dihydro-2-aryl-4-(4- isobutylphenyl)-1,5-benzothiazepine Derivatives as Anticancer and Anti-EGFR Tyrosine Kinase Agents." Anti-Cancer Agents in Medicinal Chemistry 20, no. 9 (2020): 1115–28. http://dx.doi.org/10.2174/1871520620666200130091142.

Full text

Abstract:

Background: Despite the availability of a variety of chemotherapeutic agents, cancer is still one of the leading causes of death worldwide because of the problems with existing chemotherapeutic agents like objectionable side effects, lack of selectivity, and resistance. Hence, there is an urgent need for the development of novel anticancer agents with high usefulness, fewer side effects, devoid of resistance and superior selectivity. Objective: The objective of this study is to synthesize a series of novel 1,5-benzothiazepine derivatives and evaluate their anticancer activity employing biological and computational methods. Methods: Twenty new benzothiazepines (BT1-BT20) were prepared by condensing different 1-(4- isobutylphenyl)ethanone chalcones with 2-amiothiophenol and evaluated for their anticancer activity by MTT assay against three cell lines including HT-29 (colon cancer), MCF-7 (breast cancer) and DU-145 (prostate cancer). These compounds were also tested for their inhibitory action against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase enzyme by taking into account of their excellent action against colon and breast cancer cell lines. Further, the structural features responsible for the activity were identified by Pharmacophorebased modelling using Schrodinger’s PHASETM software. Results: Among the 20 benzothiazepine derivatives, three compounds viz., BT18, BT19 and BT20 exhibited promising activity against the cell lines tested and the activity of BT20 was more than the standard methotrexate. Again the above three compounds showed excellent inhibitory activity with the percentage inhibition of 64.5, 57.3 and 55.8 respectively against EGFR (Epidermal Growth Factor Receptor) tyrosine kinase. PHASE identified a five-point AHHRR model for the proposed activity and the computational studies provided insights into the structural requirements for the anticancer activity and the results were consistent with the observed in vitro activity data. Conclusion: These novel benzothiazepines will be useful as lead molecules for the further development of new cancer therapies against colon and breast cancers.

APA, Harvard, Vancouver, ISO, and other styles

6

Abdelazeem, Ahmed H., Yasser M. A. Mohamed, Ahmed M. Gouda, Hany A. Omar, and Majed M. Al Robaian. "Novel Thymohydroquinone Derivatives as Potential Anticancer Agents: Design, Synthesis, and Biological Screening." Australian Journal of Chemistry 69, no. 11 (2016): 1277. http://dx.doi.org/10.1071/ch16102.

Full text

Abstract:

The safety and efficacy of naturally occurring anticancer agents and their derivatives such as thymoquinone (TQ) and thymohydroquinone (THQ) have gained a rapidly growing interest. In an attempt to develop novel anticancer agents with superior activity, TQ was allowed to react with hydrazine hydrate, producing hydrazino thymohydroquinone 3. This new intermediate was subsequently reacted with various isocyanates, isothiocyanates, and acyl halides, affording three series of semicarbazone, semithiocarbazone, and acyl hydrazone derivatives, respectively. Subsequently, the anticancer activity of all the newly synthesised compounds against a panel of cancer cell lines was evaluated. Initial screening of the ability of the test compounds to inhibit cancer cell viability using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay revealed that compounds 5d and 6 exerted better activity against breast cancer than TQ, with half-maximal inhibitory concentration (IC50) values of 9.6 and 10.0 μM, respectively. MTT results were confirmed by the ability of these compounds to elicit apoptotic cell death through the activation of caspase 3/7 enzymes. Together, the present work provided a novel class of THQ-based derivatives with potent anticancer and apoptosis properties, thereby warranting further optimisation of these derivatives as novel members in cancer treatment protocols.

APA, Harvard, Vancouver, ISO, and other styles

7

Anders, Carey K., Nicole R. LeBoeuf, Lara Bashoura, Saadia A. Faiz, Afreen I. Shariff, and Alexandra Thomas. "What’s the Price? Toxicities of Targeted Therapies in Breast Cancer Care." American Society of Clinical Oncology Educational Book, no. 40 (May 2020): 55–70. http://dx.doi.org/10.1200/edbk_279465.

Full text

Abstract:

Agents with mechanisms novel to breast cancer care have been approved to treat breast cancer. These agents include drugs that target cyclin-dependent kinases, phosphoinositide 3-kinase PI3KCA gene mutations, PARP, checkpoint regulation, and novel antibody-drug conjugates. However, these novel approaches bring a risk of toxicities quite different from those of conventional cytotoxic chemotherapy. Here, we review these agents and discuss related adverse events, with particular attention to endocrine, pulmonary, and dermatologic toxicities. Endocrine toxicities associated with novel cancer therapies for breast cancer are distinct and often present with symptoms related to the specific hormonal deficiencies and rarely hormonal excess. Given the complex and sometimes irreversible nature of these toxicities, once recognized, transdisciplinary management with an endocrinologist experienced with managing drug-related toxicities is encouraged. Drug-related pneumonitis is a serious concern with new targeted therapies. Presentation may not be easily distinguished, and a multidisciplinary team approach can optimize patient care. Heightened awareness is crucial for early detection and treatment. Management should follow recommendations provided by the National Cancer Institute Common Terminology Criteria for Adverse Events and agent-specific guidelines. Cutaneous toxicities from anticancer therapies represent a common and often poorly characterized challenge for patients with breast cancer. Although our understanding of dermatologic effects from novel therapies continues to improve, the breadth of toxicities spans all dermatologic conditions. Targeted therapies offer effective and often novel therapeutic strategies for patients with breast cancer but also bring new adverse event profiles. In this era, it will be important both to closely follow monitoring recommendations and to remain vigilant for emerging toxicities.

APA, Harvard, Vancouver, ISO, and other styles

8

Ahsan, Mohamed Jawed, Jyotika Sharma, Monika Singh, Surender Singh Jadav, and Sabina Yasmin. "Synthesis and Anticancer Activity ofN-Aryl-5-substituted-1,3,4-oxadiazol-2-amine Analogues." BioMed Research International 2014 (2014): 1–9. http://dx.doi.org/10.1155/2014/814984.

Full text

Abstract:

In continuance of our search for anticancer agents, we report herein the synthesis and anticancer activity of some novel oxadiazole analogues. The compounds were screened for anticancer activity as per National Cancer Institute (NCI US) protocol on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers cell lines.N-(2,4-Dimethylphenyl)-5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-amine (4s) showed maximum activity with mean growth percent (GP) of 62.61 and was found to be the most sensitive on MDA-MB-435 (melanoma), K-562 (leukemia), T-47D (breast cancer), and HCT-15 (colon cancer) cell lines with GP of 15.43, 18.22, 34.27, and 39.77, respectively. Maximum GP was observed on MDA-MB-435 (melanoma) cell line (GP=6.82) by compoundN-(2,4-dimethylphenyl)-5-(4-hydroxyphenyl)-1,3,4-oxadiazol-2-amine (4u).

APA, Harvard, Vancouver, ISO, and other styles

9

Gaber, Ahmed, Walaa F. Alsanie, Deo Nandan Kumar, Moamen S. Refat, and Essa M. Saied. "Novel Papaverine Metal Complexes with Potential Anticancer Activities." Molecules 25, no. 22 (2020): 5447. http://dx.doi.org/10.3390/molecules25225447.

Full text

Abstract:

Cancer is one of the leading causes of death worldwide. Although several potential therapeutic agents have been developed to efficiently treat cancer, some side effects can occur simultaneously. Papaverine, a non-narcotic opium alkaloid, is a potential anticancer drug that showed selective antitumor activity in various tumor cells. Recent studies have demonstrated that metal complexes improve the biological activity of the parent bioactive ligands. Based on those facts, herein we describe the synthesis of novel papaverine–vanadium(III), ruthenium(III) and gold(III) metal complexes aiming at enhancing the biological activity of papaverine drug. The structures of the synthesized complexes were characterized by various spectroscopic methods (IR, UV–Vis, NMR, TGA, XRD, SEM). The anticancer activity of synthesized metal complexes was evaluated in vitro against two types of cancer cell lines: human breast cancer MCF-7 cells and hepatocellular carcinoma HepG-2 cells. The results revealed that papaverine-Au(III) complex, among the synthesized complexes, possess potential antimicrobial and anticancer activities. Interestingly, the anticancer activity of papaverine–Au(III) complex against the examined cancer cell lines was higher than that of the papaverine alone, which indicates that Au-metal complexation improved the anticancer activity of the parent drug. Additionally, the Au complex showed anticancer activity against the breast cancer MCF-7 cells better than that of cisplatin. The biocompatibility experiments showed that Au complex is less toxic than the papaverine drug alone with IC50 ≈ 111 µg/mL. These results indicate that papaverine–Au(III) complex is a promising anticancer complex-drug which would make it a suitable candidate for further in vivo investigations.

APA, Harvard, Vancouver, ISO, and other styles

10

Alvarez, Ricardo H., Vicente Valero, and Gabriel N. Hortobagyi. "Emerging Targeted Therapies for Breast Cancer." Journal of Clinical Oncology 28, no. 20 (2010): 3366–79. http://dx.doi.org/10.1200/jco.2009.25.4011.

Full text

Abstract:

Increased understanding of the molecular events involved in cancer development has led to the identification of a large number of novel targets and, in parallel, to the development of multiple approaches to anticancer therapy. Targeted therapy focuses on specific molecules in the malignant cell signal transduction machinery, including crucial molecules involved in cell invasion, metastasis, apoptosis, cell-cycle control, and tumor-related angiogenesis. In breast cancer, two new targeted agents have recently been approved: lapatinib, directed against the human epidermal growth factor receptor 2 (HER2); and bevacizumab, directed against vascular endothelial growth factor (VEGF). Multiple other targeted agents are under evaluation in clinical trials, including inhibitors of the epidermal growth factor receptor (EGFR), dual EGFR and HER2 inhibitors, other VEGF or VEGF-receptor inhibitors, and agents that alter crucial signaling pathways, such as RAS/MEK/ERK; phosphatidylinositol-3-kinase/Akt/ mammalian target of rapamycin; insulin-like growth factor/insulin-like growth factor receptor; poly (ADP-ribose) polymerase 1; and others. In this review, we present the most promising studies of these new targeted therapies and novel combinations of targeted therapies with traditional cytotoxic agents.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Breast cancer; Novel anticancer agents"

1

Wrigley, Samantha. "Investigations of the subtle and selective antitumour properties of 2-(4-aminophenyl)-benzothiazole and related compounds." Thesis, University of Nottingham, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.338529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Weng, Shu-Chuan. "Preclinical exploration of novel small molecules as anticancer agents in triple-negative and HER2/neu-positive breast cancers." The Ohio State University, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=osu1227727553.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Koegle, Eric Richard. "Determining the Intracellular Localization and Efficacy of Novel Anticancer Agents in Human Breast Cancer Cell Lines Through the Use of Fluorescent Microscopy." Connect to full text in OhioLINK ETD Center, 2008. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=toledo1234749487.

Full text

Abstract:

Thesis (M.S.)--University of Toledo, 2008.<br>Typescript. "Submitted as partial fulfillments of the requirements for The Master of Science in Pharmaceutical Sciences in Pharmacology and Toxicology." "A thesis entitled"--at head of title. Bibliography: leaves 47-49.

APA, Harvard, Vancouver, ISO, and other styles

4

Adams, Nyssa R. "Protein targets of two novel anticancer agents." Ohio University Honors Tutorial College / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=ouhonors1311102442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hsu, Wen-Chuan. "The synthesis and investigation of novel bioreductive anticancer agents." Thesis, Cardiff University, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.344012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lee, Jisun. "Omega-3 fatty acid derived endocannabinoids as anticancer agents in breast cancer." Thesis, University of Aberdeen, 2015. http://digitool.abdn.ac.uk:80/webclient/DeliveryManager?pid=225938.

Full text

Abstract:

Many studies have reported the anti-cancer effects of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFAs). In this study, the anticancer effects of n-3 LCPUFAs and their derivatives, n-3 n-acyl ethanolamides (n-3 NAEs) were investigated in MCF-7 and MDA-MB-231 breast cancer cell lines. The focus was on their effects on cell proliferation, the role of CB1 and CB2 receptors, the effects of their main metabolising enzyme, FAAH, and which molecular signalling pathways are involved. In addition, the effects on the redox system, particularly in the modulation of redox genes, proteins and enzymes, the role of epigenetic regulation, and the effects on cell invasion and migration were also investigated. The results showed that n-3 NAEs were more potent than their parent LCPUFAs at reducing cell viability while the effects of both n-3 LCPUFAs and n-3 NAEs appear to be CB receptor mediated. In addition, MAPK pathways were also affected to varying extents following treatment, in particular p38 and JNK. Furthermore, global methylation, antioxidant gene expression, migration and invasion were in general all modulated by treatment. However, the effects observed were found to be both treatment- and cell- type dependent. Nevertheless, these results confirm that n-3 LCPUFAs and n-3 NAEs inhibit breast cancer cell growth, and modulate important cancer related pathways albeit by different mechanisms. This suggests that dietary intervention with cheap, safe, readily available fatty acids could be introduced to breast cancer patients to enhance treatment.

APA, Harvard, Vancouver, ISO, and other styles

7

Lewis, Andrew Martin. "The synthesis and biological evaluation of a novel anticancer small molecule." Thesis, University of Cambridge, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.607805.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Jodrell, Duncan Ian. "The pharmacology and toxicology of novel thymidylate synthase inhibitors, potential new anticancer agents." Thesis, University of Southampton, 1990. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.296525.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Abukhattala, Emhemed Mohamed. "Ursolic acid and oleanolic acid as novel therapeutic agents in breast cancer." University of the Western Cape, 2015. http://hdl.handle.net/11394/5053.

Full text

Abstract:

Philosophiae Doctor - PhD<br>Breast cancer is one of the most common cancers among women in South Africa and the second leading cause of cancer death after lung cancer. According to the American Cancer Society 2015, women have a 12% chance of developing invasive breast cancer and a 3% chance of dying from it. Despite the wide variety of breast cancers e.g. lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS), many share the same etiology and target tissue. Estrogen related carcinogenesis with regard to breast cancer typically results from the activation of distinct signalling pathways. These pathways are not mutually exclusive and are often constituted by receptor mediated stimulation of cell proliferation caused by specific transcriptional gene activation, reactive oxygen species (ROS) formation causing DNA damage and consequently mutations. The molecular pathways that cause drug resistance are not fully understood and the search continues to find novel targets for treatment. The effects of non-toxic triterpenes, oleanolic acid and ursolic acid and the role of autophagy and apoptosis as mechanisms to overcome drug resistance in breast cancer were studied in vitro in MCF-7 breast cancer cells and MCF10A breast cells. In this study the first aim was to establish the influence of OA and UA on cell growth and to see if opposing proliferation patterns could observed between the presumably ERɑ negative (ERɑ/ß -/+) MCF-10A and ERɑ positive (ERɑ/ß +/+) MCF-7 cells. This was followed by morphology studies to establish the possible presence of cytotoxicity and examination of molecular pathways contributing to the anti-cancerous properties of UA and OA and their validity as therapeutic agents. The MCF-7 breast cancer cell line and the immortalized normal mammary cell line, MCF-10A were treated with different concentrations of UA and OA for 6hrs, 12hrs, 24hrs, 48hrs, and 72hrs respectively. Cell morphology was studied in hematoxylin and eosin as well as Hoechst and acridine orange stained cells and viability was measured using crystal violet staining. Molecular techniques employed included the Tali® Apoptosis - and the cellROX assays, flow cytometry and western blotting. Morphological, viability and apoptotic studies have shown that at their lowest concentration, both UA and OA have anti-proliferative and apoptotic effects on MCF-7 and to a lesser extent on MCF-10A. Flow cytometric analysis of treated cells has demonstrated cell arrest in the S- and G2/M phase. The MCF-7 and MCF-10A cells growth inhibition effect may be due to increased autophagy and apoptosis as an alternative to decreased proliferation in MCF-7 cells. This possibility should be evaluated in further studies. The results showed that UA was more effective OA in decreasing cell numbers and it may be applied as treatment for breast cancer. Our observation has shown the treatment with OA and UA increased cell death in MCF-7 cells.The opposing proliferation patterns observed between the presumably ERɑ negative (ERɑ/ß -/+) MCF-10A and ERɑ positive (ERɑ/ß +/+) MCF-7 cells could possibly be ascribed to ERß forming homodimers that may facilitate proliferation, whereas ERɑ/ß heterodimers (expressed in 59% of breast cancers) are frequently associated with the ERɑ antagonising actions of ERß. The results indicate a trend towards biphasic and anti- proliferative effects of the reactants in breast cancer cells which may contribute towards the development of anti- cancer therapies. However, further work is must be done to identify the OA and UA mechanism(s) responsible for anticancer activity.<br>Libyan Embassy

APA, Harvard, Vancouver, ISO, and other styles

10

Ye, Weiping. "Mechanisms of anticancer activities of (-)-gossypol-enriched cottonseed oil against human breast cancer cells." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1174672705.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Breast cancer; Novel anticancer agents"

1

International Symposium on Novel Approaches in Cancer Therapy (1993 Heidelberg, Germany). Novel approaches in anticancer drug design: Molecular modelling, new treatment strategies : International Symposium on Novel Approaches in Cancer Therapy, Heidelberg, December 1-4, 1993. Edited by Zeller W. J, D'Incalci Maurizio, and Newell David R. Karger, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sheldon, Katherine. Breast cancer: Market opportunities for novel diagnostic and therapeutic approaches (D & MD reports). D & MD, 2001.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Atta-ur-Rahman and Khurshid Zaman, eds. Topics in Anti-Cancer Research: Volume 8. BENTHAM SCIENCE PUBLISHERS, 2019. http://dx.doi.org/10.2174/97898114043821190801.

Full text

Abstract:

Topics in Anti-Cancer Research covers new developments in the field of cancer. Novel drugs as anticancer agents include natural and synthetic phenazines and other anti-cancer compounds. It also encompasses the role of estrogen as endocrine disruptors and strategies targeting cancer stem cells for the treatment of different types of cancers, including myeloma and renal cell cancer. The diversity of researches and topics published in this eBook Series will be valuable to cancer researchers, clinicians, and cancer professionals aiming to develop novel anti-cancer targets for the treatment of various cancers. The topics covered in the eighth volume of this series are as follows: Novel Drugs for Multiple Myeloma Synthetic Estrogens are Endocrine Disruptors via Inhibition of AF1 Domain of ERs Recent Progress of Phenazines as Anticancer Agents Cancer Stem Cell Targeting for Anticancer Therapy: Strategies and Challenges

APA, Harvard, Vancouver, ISO, and other styles

4

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, and Gareth Morris-Stiff, eds. Oxford Handbook of Oncology. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199689842.001.0001.

Full text

Abstract:

Oxford Handbook of Oncology has been the essential go-to guide for students and practitioners in oncology for over a decade. The scientific basis and diagnosis of cancers is covered, as well as drugs, biomarkers, and the presentation and psychosocial aspects of oncology. Concise, practical, and comprehensive, there is no better companion for both common conditions and challenging emergencies. This handbook incorporates changes such as the understanding of the science of cancer, novel therapies in breast, lung, renal, and melanoma, molecular sub-classification of common solid cancers, personalized therapy approaches, new agents in hard to treat cancers, the benefits of new technologies in radiotherapy, and the emerging data on the importance of the immune response.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Breast cancer; Novel anticancer agents"

1

Pandurangan, Ashok Kumar, and Mohd Rais Mustafa. "Therapeutic Strategies of Natural Agents on Triple-Negative Breast Cancer." In Anticancer Plants: Natural Products and Biotechnological Implements. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8064-7_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

De Silva, Leanne, Bey-Hing Goh, Learn-Han Lee, and Lay-Hong Chuah. "Curcumin-Loaded Nanoparticles and Their Potential as Anticancer Agents in Breast Cancer." In Natural Bio-active Compounds. Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-7205-6_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

GALANIS, EVANTHIA. "CANCER GENE THERAPY CLINICAL TRIALS." In Novel Anticancer Agents. Elsevier, 2006. http://dx.doi.org/10.1016/b978-012088561-9/50017-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

MARKOVIC, SVETOMIR N., and ESTEBAN CELIS. "ANTIBODIES AND VACCINES AS NOVEL CANCER THERAPEUTICS." In Novel Anticancer Agents. Elsevier, 2006. http://dx.doi.org/10.1016/b978-012088561-9/50008-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

SHEIKH, M. SAEED, and YING HUANG. "INHIBITORS OF APOPTOSIS AS TARGETS FOR CANCER THERAPY." In Novel Anticancer Agents. Elsevier, 2006. http://dx.doi.org/10.1016/b978-012088561-9/50009-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

ZHANG, RUIWEN, and HUI WANG. "ANTISENSE STRATEGIES FOR THE DEVELOPMENT OF NOVEL CANCER THERAPEUTICS." In Novel Anticancer Agents. Elsevier, 2006. http://dx.doi.org/10.1016/b978-012088561-9/50007-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

McCluskey, Adam, and Cecilia Russell. "Chalcones: Potential Anticancer Agents." In Translational Research in Cancer. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.91441.

Full text

Abstract:

Chalcones in their various guises have been considered either valid and critically important lead compounds in the development of novel anticancer agents or as pan assay interference compounds, PAINS. Medicinal chemistry is replete with exemplars from both “camps” progressing to clinical utility. Chalcones offer a simple starting point for the development of specific compounds with high levels of activity toward key biological targets. Chalcones have been shown to display a wide array of anticancer compounds. This chapter seeks to offer an overview of key examples in an effort to encourage further reading and research in development in this intriguing space.

APA, Harvard, Vancouver, ISO, and other styles

8

"Selective Estrogen Receptor Modulators as Treatments and Preventives of Breast Cancer." In Advances in Anticancer Agents in Medicinal Chemistry, edited by Surojeet Sengupta, Jing Peng, and Virgil C. Jordan. BENTHAM SCIENCE PUBLISHERS, 2013. http://dx.doi.org/10.2174/9781608054961113020010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

de Fátima Braga Magalhães, Isadora, Kátia da Silva Calabrese, Ana Letícia Marinho Figueirêdo, Ana Lucia Abreu-Silva, and Fernando Almeida-Souza. "The Use of Plants’ Natural Products in Breast Cancer: Have We Already Found the New Anticancer Drug?" In Breast Cancer [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.96404.

Full text

Abstract:

The importance of a new anticancer drug for breast cancer is well established. Natural compounds that can prevent this disease or be used as an adjuvant treatment associated with conventional drugs could be the solution for this. This chapter is an overview of agents extracted from plants with outstand results in the last six years. Green tea, berberine, thymoquinone and cannabidiol are compounds isolated from medicinal plants. These agents showed action through induction of apoptosis, down regulation of inflammation, epigenetics, hormonal modulation, among other. In vitro effect against cancer cells, in vivo experiments mainly with murine model and clinical trials reassured their efficacy against breast cancer. A protective effect against recurrence cases and chemosensitization to standard drugs was also successful. The use of nanotechnology provided a optimize delivery of these therapeutical molecules. Taken together this information led us to acknowledgement that we do probably have the natural agents for a future adjuvant treatment against breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

10

Dutta, Sayanta, Sushweta Mahalanobish, and Parames C. Sil. "Phytoestrogens as Novel Therapeutic Molecules Against Breast Cancer." In Discovery and Development of Anti-Breast Cancer Agents from Natural Products. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-12-821277-6.00008-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Breast cancer; Novel anticancer agents"

1

Hawthorne, Tamorah, Joseph Gallien, Lee Gibbs, et al. "Abstract 4606: An in vitro and in vivo evaluation of novel anticancer agents in a triple negative breast cancer model." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-4606.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Jong, Ling, Wan-ru Chao, Yihui Shi, Carol Green, Lidia Sambucetti, and Nathan Collins. "Abstract 3563: Novel anticancer agents modulate multiple signal transduction pathways for cancer therapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-3563.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Miceli, Cristina, Lijin Chen, and Sucharita J. Mistry. "Abstract 2792: Novel anti-microtubule agents for breast cancer." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2792.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

McCarthy, Florence, Charlotte Miller, and Elaine O'Sullivan. "Novel 11-substituted ellipticines as potent anticancer agents with divergent activity against cancer cells." In 6th International Electronic Conference on Medicinal Chemistry. MDPI, 2020. http://dx.doi.org/10.3390/ecmc2020-07802.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mirza, Sameer, Gayatri Sharma, Kalpana Luthra, and Ranju Ralhan. "Abstract A48: Demethylating agent 5-Aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents." In Abstracts: AACR International Conference on Translational Cancer Medicine-- Jul 11-14, 2010; San Francisco, CA. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1078-0432.tcmusa10-a48.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Radomska, Dominika, Dominik Radomski, Robert Czarnomysy, and Krzysztof Bielawski. "Anticancer activity of novel selenoesters in MCF-7 and MDA-MB-231 human breast cancer cells." In RAD Conference. RAD Centre, 2021. http://dx.doi.org/10.21175/rad.abstr.book.2021.8.5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Zakai, Uzma I., Stephen Gately, and Robert West. "Abstract C50: Novel silicon derivatives of indomethacin: Generation of potent COX‐2 selective agents with improved anticancer activity." In Abstracts: First AACR International Conference on Frontiers in Basic Cancer Research--Oct 8–11, 2009; Boston MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.fbcr09-c50.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Yawson, Emmanuel, Angel Garcia, Husamuldeen Dhari, and Rajendram V. Rajnarayanan. "Abstract 3240: Designer peptides targeting epidermal growth factor as novel anti-breast cancer agents." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-3240.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Döpkens, Mailin, Tiffany R. Blackwell, Farhad Vesuna, et al. "Abstract 652: Magnetic resonance spectroscopy detects silencing of the novel anticancer target GDPD5 in human breast cancer cells." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-652.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Mayer, Ingrid A. "Abstract ES3-3: Integration of novel targeted agents with endocrine therapy." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-es3-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Breast cancer; Novel anticancer agents"

1

Mistry, Sucharita. Novel Antimicrotubule Agents for Breast Cancer. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada555313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pagel, Mark. Novel Molecular Imaging Agents to Detect Biomarkers of Metastatic Breast Cancer. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada458457.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Van Brocklin, Henry F. Development of novel epidermal growth receptor-basedradiopharmaceuticals: Imaging agents for breast cancer. Office of Scientific and Technical Information (OSTI), 2001. http://dx.doi.org/10.2172/920326.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Richards, Talmesha. Polyamine Analogues as Novel Anti-HER Family Agents in Human Breast Cancer. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada513832.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Mirica, Liviu M., and Barbara Casella. Specific Inhibitors of Histone Demethylases: Novel Chemical Agents for Breast Cancer Therapy. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada576183.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Richards, Talmesha. Polyamine Analogues as Novel Anti-HER Family Agents in Human Breast Cancer. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada477006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Hanson, Robert N. Development of Novel Technetium-99m-Labeled Steroids as Estrogen-Responsive Breast Cancer Imaging Agents. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada474746.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Macedo, Luciana, and Linda Malkas. The Human Breast Cancer DNA Synthesome Can Serve as a Novel In Vitro Model System for Studying the Mechanism of Action of Anticancer Drugs. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada393926.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jiang, Haiyan. The Human Breast Cancer Cell DNA Synthesome Can Serve as a Novel in Vitro Model System for Studying the Mechanism of Action of Anticancer Drugs. Defense Technical Information Center, 1999. http://dx.doi.org/10.21236/ada384124.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!